Pharmaceutical Industries went to the Executive Yuan, and had made solemn protest to the President Wu Den–yih.
The 7th reduction of Pharmaceutical Benefit for National Health Insurance may compel about two hundred medicines to withdraw from the Taiwan market. People will confront by no drug to use and injury the safety of drug use, and it will influence the interests of medicine use for the public.
Lee Shu-Ping, the president of TPIP, went to the Executive Yuan and had made solemn protest to the President Wu Den–yih on Nov. 17. They required the Executive Yuan should postpone the implement of the reduction of pharmaceutical benefit for three months, re-examine the adjustment principle and the complete supporting of pharmaceutical benefit, and consider avoiding the effect on the safety of drug use for the public. He had two queries about “if people have to
confront by no drug to use, and who will control the interests of medicine use for the public?” and “each time the reduction of Pharmaceutical Benefit for National Health Insurance is extremely unlikely to use for the safety of drug use”.
Heavy rain poured didn’t put out the wrath from pharmaceutical industries, and hundred of pharmacists had went to the street in the rain to protest against “the reduction of pharmaceutical benefit resulted in people have to face to the situation with no drug to use”. Also, they spoke so loud to ask the relative units do not ignore the question that “the pharmaceutical benefit will affect the drug use for the public” again, and they shall re-consider the completely overall supporting of the reduction of pharmaceutical benefit.
Su Yong-fu, the group leader of 1st group in the Executive Yuan, had given an interview to the representative of the pharmaceutical industry. And he will deliver over the provision of petition and appeal to the President Wu Den
–yih. The pharmaceutical industry has expected that the medication environment would get chance to give people back “drugs available” again in a short time.
Lee Shu-Ping also emphasized that the adjustment system of pharmaceutical benefit has been unavailable to meet the actual requirement, and each time the pharmaceutical benefit which had lowered by National Health Insurance should be necessary to review again.
To maintain the safety of drug use for the public, TPIP has expected that Bureau of National Health Insurance could re-examine and adjust the system to assure people with drugs available and create an environment for drug safety.